May 3 (Reuters) – Swiss dental implant maker Straumann Holding on Wednesday reported organic sales growth of 3.4% for the first quarter, helped by robust demand across most of its markets.
The dental healthcare company confirmed its outlook of organic sales growth in the high-single-digit percentage range in 2023, 큐프라임치과 and profitability at around 25% including growth investments.
“We are confirming our full-year outlook despite the uncertainties around potential economic and geopolitical impacts,” CEO Guillaume Daniellot said in a statement.
The company said all geographies performed well in the first quarter, except for China, where the combined impact of COVID-19 lockdowns, lagging patient flows, and the Chinese Volume-Based Procurement (VBP) pricing hampered growth.
A tender programme for healthcare products aimed at lowering costs for consumers, China’s VBP has driven average selling prices to a much lower level.
Sales plunged 23.5% in Asia-Pacific (APAC), including China, Straumann’s key market in the region. Excluding China, APAC delivered a “solid performance”, the company added.
The company, which specialises in tooth replacement and orthodontic solutions, reported revenue of 596 million Swiss francs ($668.84 million) in the three months to the end of March, compared with 588.9 million francs a year ago.
($1 = 0.8911 Swiss francs) (Reporting by Andrey Sychev and 큐프라임치과 Anna Mackenzie in Gdansk; Editing by Christian Schmollinger and Rashmi Aich)
